Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tito Fojo

Showing results (31-40 of 237) with videos related to

Pageof 24
Sort By:
Journal of the National Cancer Institute|February 14, 2008
Is there room for improvement in adverse event reporting in the era of targeted therapies?Maureen Edgerly, Tito Fojo
Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 23, 2013
Renal cell carcinoma: trying but failing to improve the only curative therapyNicolas Acquavella, Tito Fojo
The Oncologist|August 28, 2016
BEZ235: When Promising Science Meets Clinical RealityGeorgios Pongas, Tito Fojo
Seminars in Oncology|September 20, 2017
Long-acting somatostatin analogues in the treatment of unresectable/metastatic neuroendocrine tumorsThomas Enzler, Tito Fojo
Nature Reviews. Clinical Oncology|October 15, 2014
Decade in review-funding in cancer research: National Cancer Institute awards-a work in progressTito Fojo, Paraskevi Giannakakou
Seminars in Oncology|June 25, 2018
CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclibBahar Laderian, Tito Fojo
Surgical Oncology Clinics of North America|August 3, 2006
Treatment of metastatic disease in patients with neuroendocrine tumorsJohn E Niederhuber, Tito Fojo
Seminars in Oncology|December 20, 2005
Microtubule targeting agents: basic mechanisms of multidrug resistance (MDR)Antonio Tito Fojo, Michael Menefee
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2005
Epidermal growth factor receptor inhibitors: a moving target?Susan E Bates, Tito Fojo
The Oncologist|November 13, 2013
Acetyl-L-carnitine and prevention of chemotherapy-induced peripheral neuropathy: can anything work?Mauricio Burotto, Antonio Tito Fojo
Pageof 24

Showing results (31-40 of 237) with videos related to

Sort By:
Pageof 24
Journal of the National Cancer Institute|February 14, 2008
Is there room for improvement in adverse event reporting in the era of targeted therapies?Maureen Edgerly, Tito Fojo
Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 23, 2013
Renal cell carcinoma: trying but failing to improve the only curative therapyNicolas Acquavella, Tito Fojo
The Oncologist|August 28, 2016
BEZ235: When Promising Science Meets Clinical RealityGeorgios Pongas, Tito Fojo
Seminars in Oncology|September 20, 2017
Long-acting somatostatin analogues in the treatment of unresectable/metastatic neuroendocrine tumorsThomas Enzler, Tito Fojo
Nature Reviews. Clinical Oncology|October 15, 2014
Decade in review-funding in cancer research: National Cancer Institute awards-a work in progressTito Fojo, Paraskevi Giannakakou
Seminars in Oncology|June 25, 2018
CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclibBahar Laderian, Tito Fojo
Surgical Oncology Clinics of North America|August 3, 2006
Treatment of metastatic disease in patients with neuroendocrine tumorsJohn E Niederhuber, Tito Fojo
Seminars in Oncology|December 20, 2005
Microtubule targeting agents: basic mechanisms of multidrug resistance (MDR)Antonio Tito Fojo, Michael Menefee
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2005
Epidermal growth factor receptor inhibitors: a moving target?Susan E Bates, Tito Fojo
The Oncologist|November 13, 2013
Acetyl-L-carnitine and prevention of chemotherapy-induced peripheral neuropathy: can anything work?Mauricio Burotto, Antonio Tito Fojo
Pageof 24